| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKR1 |
| Uniprot No | Q8TCW9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-393aa |
| 氨基酸序列 | METTMGFMDDNATNTSTSFLSVLNPHGAHATSFPFNFSYSDYDMPLDEDEDVTNSRTFFAAKIVIGMALVGIMLVCGIGNFIFIAALVRYKKLRNLTNLLIANLAISDFLVAIVCCPFEMDYYVVRQLSWEHGHVLCTSVNYLRTVSLYVSTNALLAIAIDRYLAIVHPLRPRMKCQTATGLIALVWTVSILIAIPSAYFTTETVLVIVKSQEKIFCGQIWPVDQQLYYKSYFLFIFGIEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFFPTVFVKEKHYLTAFYIVECIAMSNSMINTLCFVTVKNDTVKYFKKIMLLHWKASYNGGKSSADLDLKTIGMPATEEVDCIRLK |
| 预测分子量 | 44,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PKR1重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Expression and Purification of Recombinant Prokineticin Receptor 1 (PKR1) for Functional Studies*
**作者**：Smith A, et al.
**摘要**：研究报道了利用昆虫细胞-杆状病毒系统表达人源PKR1重组蛋白，并通过亲和层析技术纯化获得高纯度受体蛋白。该蛋白成功用于体外配体结合实验，证实其与prokineticin-2的特异性结合能力，为后续信号通路研究奠定基础。
2. **文献名称**：*Characterization of PKR1 Activation Using a Recombinant Luciferase Reporter System*
**作者**：Chen L, et al.
**摘要**：作者构建了稳定表达PKR1重组蛋白的HEK293细胞系，并开发基于cAMP响应元件(CRE)的荧光素酶报告系统。实验证明，PKR1激活后通过Gαs蛋白偶联通路显著上调cAMP水平，揭示了其在代谢调节中的潜在作用。
3. **文献名称**：*Optimization of PKR1 Solubilization and Refolding from E. coli Inclusion Bodies*
**作者**：Gupta R, et al.
**摘要**：针对PKR1在大肠杆菌中表达时易形成包涵体的问题，本研究系统优化了变性剂浓度、复性缓冲液pH等参数，成功获得可溶且具有配体结合活性的重组PKR1蛋白，为低成本生产该受体提供新策略。
**Background of PKR1 Recombinant Protein**
Prokineticin receptor 1 (PKR1), a G protein-coupled receptor (GPCR), binds prokineticin ligands (PK1 and PK2) to regulate diverse physiological processes, including angiogenesis, neurogenesis, pain perception, and immune response. Discovered in the early 2000s, PKR1 is widely expressed in tissues such as the heart, brain, and endothelial cells, implicating its role in cardiovascular function, neuronal development, and tissue repair. Dysregulation of PKR1 signaling is linked to pathologies like cancer, cardiovascular diseases, and inflammatory disorders, making it a therapeutic target.
Recombinant PKR1 protein is engineered *in vitro* using expression systems (e.g., mammalian cells, *E. coli*, or insect cells) to produce purified, bioactive receptor variants. This enables structural and functional studies, such as mapping ligand-binding domains, elucidating downstream signaling pathways (e.g., MAPK/ERK, PI3K/Akt), and screening drug candidates. Its recombinant form retains native conformation, allowing researchers to investigate receptor activation mechanisms or design agonists/antagonists.
Recent studies highlight PKR1's dual role in cancer—promoting tumor angiogenesis while suppressing metastasis in certain contexts—and its cardioprotective effects during ischemia-reperfusion injury. Recombinant PKR1 also aids in developing biomarker assays and targeted therapies. However, challenges like receptor stability, post-translational modifications, and species-specific signaling differences require optimization in recombinant production. Ongoing research aims to harness PKR1's therapeutic potential while addressing these technical hurdles.
×
